Voyager Therapeutics (FRA:VT6) Stock Based Compensation: €11.69 Mil (TTM As of Mar. 2026)


FRA:VT6 Voyager Therapeutics Inc FRA:VT6
53 GF Score
Price €3.16
GF Value €1.40
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Voyager Therapeutics Stock Based Compensation?

Voyager Therapeutics FRA:VT6 +5.20% 53 Stock Based Compensation is €11.69 Mil as of Mar. 2026. GuruFocus rates FRA:VT6 with a GF Score™ of 53/100 and a GF Value™ of €1.40 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Voyager Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was €2.15 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €11.69 Mil.

Voyager Therapeutics Stock Based Compensation Related Terms

Voyager Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Stock Based Compensation Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.02 8.82 10.23 14.12 12.63

Voyager Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.40 3.58 2.95 3.01 2.15
FRA:VT6
53GF Score
Voyager Therapeutics Inc FRA:VT6
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.69 Mil.

What does a Stock Based Compensation of €11.69 Mil mean?
Voyager Therapeutics (FRA:VT6) has a Stock Based Compensation of €11.69 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' Stock Based Compensation too high?
Voyager Therapeutics' current Stock Based Compensation is €11.69 Mil. Overall, Voyager Therapeutics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Stock Based Compensation compare to KROS and CDXS?
Voyager Therapeutics' Stock Based Compensation of €11.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Voyager Therapeutics and its competitors. Voyager Therapeutics's current Stock Based Compensation is €11.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.40, compared to a current price of €3.16 — trading 125.6% above its estimated fair value. The current Stock Based Compensation is €11.69 Mil. Voyager Therapeutics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Stock Based Compensation is €11.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.16 is trading 125.6% above its estimated GF Value™ of €1.40. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Stock Based Compensation: €11.69 Mil
  • GF Value™: €1.40 vs. price of €3.16 (125.6% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
53GF Score

Get the complete analysis for FRA:VT6

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.16
Price
€1.40
GF Value